C3 glomerulopathy: A new complement-based entity
A de Lorenzo1, S Tallón1, B Hernández-Sevillano1
1Servicio de Nefrología, Hospital Universitario de Guadalajara, Departamento de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, España.
Insights
C3 glomerulopathy, a kidney disease involving complement alternative pathway dysregulation, includes dense-deposit disease and C3 glomerulonephritis. Eculizumab shows promise in treating this condition, particularly in young patients.
Area of Science:
- Nephrology
- Immunology
- Complement System
Background:
- C3 glomerulopathy is a newly defined kidney disease encompassing dense-deposit disease and C3 glomerulonephritis.
- The alternative complement pathway is central to its pathogenesis, often due to genetic defects or autoantibodies.
- Poor prognosis and early onset in young individuals necessitate novel therapeutic strategies.
Purpose of the Study:
- To investigate the role of the complement system in C3 glomerulopathy.
- To evaluate the effectiveness of new therapeutic agents for C3 glomerulopathy.
Main Methods:
- Analysis of complement pathway dysregulation in C3 glomerulopathy.
- Clinical assessment of patients treated with eculizumab.
Main Results:
- Mutations in complement regulatory factors (factor H, I) and C3 nephritic factor cause uncontrolled complement activation.
- Deposition of complement products in glomeruli characterizes the disease.
- Eculizumab, an anti-C5 antibody, has shown effectiveness in treating C3 glomerulopathy patients.
Conclusions:
- C3 glomerulopathy represents a significant advancement in understanding glomerular diseases.
- Targeting the complement system, specifically C5, offers a promising therapeutic avenue for C3 glomerulopathy.
Abstract:
C3 glomerulopathy is a new, recently described entity that has changed the perspective, treatment and classification of a number of glomerular diseases. It encompasses 2 similar but clearly differentiated pathologies -the dense-deposit disease and C3 glomerulonephritis itself. The alternative complement pathway plays a fundamental role in its pathogenesis and, specifically, the mutations and defects in its regulatory factors (mainly factor H and factor I), as well as the presence of acquired autoantibodies (C3 nephritic factor), which generates an unbridled activation of the system, and ultimately, a deposit of its products at the glomerular level. Its poor prognosis and onset in young populations makes the detailed study of new therapeutic alternatives for this disease essential. Recently eculizumab, an anti-C5 antibody, has demonstrated effectiveness in the treatment of these patients.
Related Concept Videos
01:27Complement System
01:19Hypersensitivity Reactions: Immune-Complex Reactions
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:24Nephrotic Syndrome I : Introduction
01:22Cerebral Edema ll: Pathophysiology
01:01Hypersensitivity Reactions: Cytolytic Reactions